A5037246812- Antibiotics Pharmacokinetics and Efficacy
- Myasthenia Gravis and Thymoma
- Pneumocystis jirovecii pneumonia detection and treatment
- Drug Transport and Resistance Mechanisms
- Social Media in Health Education
- Health Literacy and Information Accessibility
- Intensive Care Unit Cognitive Disorders
- Long-Term Effects of COVID-19
- Gastroesophageal reflux and treatments
- Asthma and respiratory diseases
- Anesthesia and Sedative Agents
- Renal function and acid-base balance
- Pneumonia and Respiratory Infections
- Mobile Health and mHealth Applications
- Respiratory and Cough-Related Research
Duke Medical Center
2023
Clinical Research Institute
2019-2021
Duke University
2021
Abstract Background Patients with myasthenia gravis (MG) may be particularly vulnerable during the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic due to risk of worsening disease infection, potential adverse impacts 2019 (COVID‐19) treatments on neuromuscular transmission, and a limited ability fight off infection related immunosuppressive treatments. Our goal is understand how patients are experiencing COVID‐19 pandemic, including where they receive relevant...
The antibiotic combination trimethoprim (TMP)-sulfamethoxazole (SMX) has a broad spectrum of activity and is used for the treatment numerous infections, but pediatric pharmacokinetic (PK) data are limited. We previously published population PK (popPK) models oral TMP-SMX in patients based on sparse opportunistically collected (POPS study) (J.
Introduction 
 We previously conducted a survey study in April 2020 at the beginning of SARS-CoV-2 (COVID-19) pandemic to understand how it affected patients with myasthenia gravis (MG). Since then, significant advances have occurred following areas: knowledge about virus, infection risk mitigation, patient management, risks for MG patients, and global vaccination program. follow-up February 2021 assess these impacted care perception patients. Methods prospective online large academic...
Adverse drug events are common in critically ill children and often result from systemic or target organ exposure. Methods of dosing titration that consider pharmacokinetic alterations may improve our ability to optimally dose patients reduce the risk for drug-related adverse events. To demonstrate this possibility, we explored exposure-response relationship between midazolam delirium children. We retrospectively examined electronic health records (EHRs) <18 years age hospitalized pediatric...